This study examines how global multiomics technologies are changing the way that cancer is treated, with a focus on new developments, strategic needs, and future directions. By facilitating thorough tumor characterization, early detection, patient stratification, and real-time monitoring, multiomics—an integrated analysis of genomics, transcriptomics, proteomics, metabolomics, and epigenomics—is transforming precision oncology. The study showcases innovative technologies like scalable cloud-based sequencing solutions, AI-integrated platforms, single-cell, and spatial multiomics. These developments are making it easier to gain dynamic insights into drug resistance, tumor heterogeneity, and immunotherapy response. Additionally, the study assesses the evolving technology, clinical, and regulatory landscapes that are influencing multiomics adoption around the world. Key enablers include AI-driven data integration, miniaturized sequencing platforms, and federated learning models, while challenges persist around data harmonization, access equity, and translational scalability. Leading innovators—from biopharma firms and AI start-ups to academic consortia—are profiled to illustrate the active innovation ecosystem. Regional trends underscore North America's dominance, Europe's robust public–private initiatives, and APAC’s rapid clinical integration of omics technologies. The report projects a large market expansion and identifies important growth prospects in single-cell analytics, spatial biology, and AI-powered diagnostics. Collectively, this study provides a comprehensive overview of the technological, strategic, and collaborative advancements driving the global evolution of multiomics in cancer research and care.